Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
New N-phenylpyrrolamide inhibitors of DNA gyrase with improved antibacterial activity
ID
Cotman, Andrej Emanuel
(
Author
),
ID
Fulgheri, Federica
(
Author
),
ID
Piga, Martina
(
Author
),
ID
Peršolja, Peter
(
Author
),
ID
Benedetto Tiz, Davide
(
Author
),
ID
Skok, Žiga
(
Author
),
ID
Durcik, Martina
(
Author
),
ID
Sterle, Maša
(
Author
),
ID
Dernovšek, Jaka
(
Author
),
ID
Zega, Anamarija
(
Author
),
ID
Peterlin-Mašič, Lucija
(
Author
),
ID
Ilaš, Janez
(
Author
),
ID
Tomašič, Tihomir
(
Author
),
ID
Kikelj, Danijel
(
Author
),
ID
Zidar, Nace
(
Author
)
PDF - Presentation file,
Download
(1,84 MB)
MD5: 550837F30EAC647EC45D64986B3196B9
URL - Source URL, Visit
https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra04802d
Image galllery
Abstract
This study presents the discovery of a new series of N-phenylpyrrolamide inhibitors of bacterial DNA gyrase with improved antibacterial activity. The most potent inhibitors had low nanomolar IC$_{50}$ values against Escherichia coli DNA gyrase (IC$_{50}$; 2–20 nM) and E. coli topoisomerase IV (22i, IC$_{50}$ = 143 nM). Importantly, none of the compounds showed activity against human DNA topoisomerase IIα, indicating selectivity for bacterial targets. Among the tested compounds, 22e emerged as the most effective against Gram-positive bacteria with minimum inhibitory concentration (MIC) values of 0.25 μg mL$^−1$ against Staphylococcus aureus ATCC 29213 and MRSA, and 0.125 μg mL$^−1$ against Enterococcus faecalis ATCC 29212. For Gram-negative bacteria, compounds 23b and 23c showed the greatest efficacy with MIC values ranging from 4 to 32 μg mL$^−1$ against E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Acinetobacter baumannii ATCC 17978 and A. baumannii ATCC 19606. Notably, compound 23b showed promising activity against the clinically relevant Gram-negative pathogen Klebsiella pneumoniae ATCC 10031, with an MIC of 0.0625 μg mL$^−1$. Furthermore, compounds 23a and 23c exhibited significantly lower susceptibility to resistance development compared to novobiocin in S. aureus ATCC 29213 and K. pneumoniae ATCC 10031. Overall, the most promising compounds of this series showed excellent on-target potency, marking a significant improvement over previous N-phenylpyrrolamide inhibitors.
Language:
English
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 28423-28454
Numbering:
Vol. 14
PID:
20.500.12556/RUL-162177
UDC:
615.4:54
ISSN on article:
2046-2069
DOI:
10.1039/d4ra04802d
COBISS.SI-ID:
206901507
Publication date in RUL:
19.09.2024
Views:
151
Downloads:
657
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
RSC advances
Publisher:
RSC Publishing
ISSN:
2046-2069
COBISS.SI-ID:
2513252
Licences
License:
CC BY 3.0, Creative Commons Attribution 3.0 Unported
Link:
https://creativecommons.org/licenses/by/3.0/deed.en
Description:
You are free to reproduce and redistribute the material in any medium or format. You are free to remix, transform, and build upon the material for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Secondary language
Language:
Slovenian
Keywords:
N-fenilpirolamidni inhibitorji
,
bakterijske DNA giraze
,
sinteza spojin
,
antibakterijsko delovanje
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P1-0208
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J1-3021
Name:
Platforma osnovana na sintetičnih biofilmih za preučevanje in razvoj novih proti biofilmskih pristopov
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J1-3031
Name:
Razvoj novih zaviralcev bakterijskih topoizomeraz za boj proti odpornim infekcijam
Funder:
AKA - Academy of Finland
Project number:
321551
Name:
Evolving the next generation of Gram-negative antimicrobials through a synergetic approach encompassing medicinal chemistry, microbiology and nanomedicine tools / Consortium: NO-ESCAPE
Funder:
Other - Other funder or multiple funders
Funding programme:
National Laboratory of Biotechnology
Project number:
2022-2.1.1-NL-2022-00008
Funder:
Other - Other funder or multiple funders
Funding programme:
Hungary, National Research Development and Innovation Office
Project number:
K146323
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back